Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rowan E Miller

Showing results (11-20 of 37) with videos related to

Pageof 4
Sort By:
Women'S Health (London, England)|December 9, 2020
Targeting HPV in gynaecological cancers - Current status, ongoing challenges and future directionsShanthini M Crusz, Karim El-Shakankery, Rowan E Miller
Rare Tumors|April 6, 2011
Lung carcinoma with hypertrophic osteoarthropathy in a teenagerRowan E Miller, Rowland O Illing, Jeremy S Whelan
The British Journal of Radiology|April 21, 2021
PARP inhibitors and immunotherapy in ovarian and endometrial cancersRowan E Miller, Amy J Lewis, Melanie E Powell
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 2, 2016
Gynecologic Cancers: Emerging Novel Strategies for Targeting DNA Repair DeficiencyRebecca S Kristeleit, Rowan E Miller, Elise C Kohn
Therapeutic Advances in Medical Oncology|June 18, 2025
Controversies and clinical unknowns in the use of PARP inhibitors in ovarian cancerUma A Mukherjee, Rowan E Miller, Jonathan A Ledermann
Cancers|October 14, 2023
The Landscape of Adoptive Cellular Therapies in Ovarian CancerLucy Davis, Rowan E Miller, Yien Ning Sophia Wong
Journal of Gynecologic Oncology|March 23, 2022
PARP inhibitors in ovarian cancer: overcoming resistance with combination strategiesRowan E Miller, Karim H El-Shakankery, Jung-Yun Lee
Current Opinion in Oncology|August 16, 2020
Role of Poly (ADP-Ribose) Polymerase inhibitors beyond BReast CAncer Gene-mutated ovarian tumours: definition of homologous recombination deficiency?Charlie Gourley, Rowan E Miller, Robert L Hollis, et al.
Oncotargets and Therapy|October 11, 2022
Ovarian Cancer Therapy: Homologous Recombination Deficiency as a Predictive Biomarker of Response to PARP InhibitorsRowan E Miller, Osnat Elyashiv, Karim H El-Shakankery, et al.
BJU International|September 29, 2012
Pathological findings after primary chemotherapy in patients undergoing simultaneous orchidectomy and retroperitoneal lymph node dissection for advanced germ cell tumoursRowan E Miller, Tim Dudderidge, Robert Huddart, et al.
Pageof 4

Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
Women'S Health (London, England)|December 9, 2020
Targeting HPV in gynaecological cancers - Current status, ongoing challenges and future directionsShanthini M Crusz, Karim El-Shakankery, Rowan E Miller
Rare Tumors|April 6, 2011
Lung carcinoma with hypertrophic osteoarthropathy in a teenagerRowan E Miller, Rowland O Illing, Jeremy S Whelan
The British Journal of Radiology|April 21, 2021
PARP inhibitors and immunotherapy in ovarian and endometrial cancersRowan E Miller, Amy J Lewis, Melanie E Powell
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 2, 2016
Gynecologic Cancers: Emerging Novel Strategies for Targeting DNA Repair DeficiencyRebecca S Kristeleit, Rowan E Miller, Elise C Kohn
Therapeutic Advances in Medical Oncology|June 18, 2025
Controversies and clinical unknowns in the use of PARP inhibitors in ovarian cancerUma A Mukherjee, Rowan E Miller, Jonathan A Ledermann
Cancers|October 14, 2023
The Landscape of Adoptive Cellular Therapies in Ovarian CancerLucy Davis, Rowan E Miller, Yien Ning Sophia Wong
Journal of Gynecologic Oncology|March 23, 2022
PARP inhibitors in ovarian cancer: overcoming resistance with combination strategiesRowan E Miller, Karim H El-Shakankery, Jung-Yun Lee
Current Opinion in Oncology|August 16, 2020
Role of Poly (ADP-Ribose) Polymerase inhibitors beyond BReast CAncer Gene-mutated ovarian tumours: definition of homologous recombination deficiency?Charlie Gourley, Rowan E Miller, Robert L Hollis, et al.
Oncotargets and Therapy|October 11, 2022
Ovarian Cancer Therapy: Homologous Recombination Deficiency as a Predictive Biomarker of Response to PARP InhibitorsRowan E Miller, Osnat Elyashiv, Karim H El-Shakankery, et al.
BJU International|September 29, 2012
Pathological findings after primary chemotherapy in patients undergoing simultaneous orchidectomy and retroperitoneal lymph node dissection for advanced germ cell tumoursRowan E Miller, Tim Dudderidge, Robert Huddart, et al.
Pageof 4